Table 1.
Demographic data of populations in Illumina (stage 1) and Sequenom (stage 2).
Table 2.
Clinical characteristics of CD Patients.
Table 3.
Summary of association of SLCO3A1 between CD cases and controls.
Table 4.
Genotype and phenotype analysis of SLCO3A1 (rs207959).
Figure 1.
rs207959 T/C elevates SLCO3A1 mRNA and protein expression levels in colon and small intestine tissue of normal, non-CD diseases, and CD patients.
(A) Expression of SLCO3A1 in colon tissue of normal (non-tumor portion of colorectal cancer patients) and CD patient by immunohistochemical staining (400X). (B) Expression of SLCO3A1 in colon tissue of different CD patient genotypes (n = 3 for TT/CC group and n = 10 for TC group) determined by quantitative PCR. (C) Expression of SLCO3A1 mRNA in colonic tissue (n = 30 for normal and colorectal cancer tumor; n = 24 for active CD patients; n = 6 for remission CD patients) determined by quantitative PCR. (D) Expression of SLCO3A1 mRNA in small intestine tissue (n = 3 for normal; n = 5 for reperfusion inflammation; n = 6 for active CD patients) determined by quantitative PCR (*P<0.05).
Figure 2.
Overexpression of SLCO3A1 induces NF-κB activation, enhances the phosphorylation of two classes of MAPKs (ERK and JNK), and augments NF-κB activity.
(A) Overexpression of SLCO3A1 induced approximately 6-fold higher NF-κB activation (**P<0.01). (B) Overexpression of SLCO3A1 in HEK293T cells resulted in increased p65 expression (*P<0.05). (C) ERK and JNK expression increased with overexpression of SLCO3A1, while expression of p38 and AKT showed no difference (*P<0.05). All experiments were performed at least 3 times.
Figure 3.
Activation of NF-κB by nicotine in SLCO3A1 overexpressing cells.
(A) HEK293T cells were transfected with the NF-κB reporter plasmids, together with an empty vector or SLCO3A1 constructs. Addition of 0.8 µM nicotine for 24 hours resulted in increased NF-κB activity in cells overexpressing SLCO3A1 (*P<0.05). (B) Western blot analysis from cell lysates demonstrates equal transfection efficiencies.